Hennigsdorf (Germany), March 12, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation in three upcoming conferences in Europe. Adrenomed representatives will be available for one-on-one meetings at these events. 12th
12th Berlin Conference on Life Science Novel Antimicrobials ans AMR Diagnostic 2019 14-15 March | Berlin, Germany Link to the Conference
Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock Adrecizumab is a first-in-class antibody targeting Adrenomedullin, to rescue vascular function Vascular integrity, regulated by Adrenomedullin, is key to preventing vascular leakage and septic shock
Published in the January 2019 edition of MedNous, a publication of Evernow Publishing Ltd.